Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE vs MINIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.
Desmopressin is a synthetic analog of antidiuretic hormone (ADH) that increases water reabsorption in the renal collecting ducts by binding to V2 receptors, leading to increased aquaporin-2 expression and reduced urine output.
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type 1)
Central diabetes insipidus,Nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type I)
Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.
Adults: 1-2 sprays intranasally (10 mcg each) once daily; for diabetes insipidus, 1-2 sprays once or twice daily. Oral: 0.1-0.2 mg three times daily.
Terminal elimination half-life is approximately 3-4 hours in healthy adults, but may be prolonged in patients with renal impairment or in older adults.
Terminal elimination half-life: 2–3 hours (intravenous, subcutaneous); 3–5 hours (oral). Clinical context: Short half-life necessitates frequent dosing; duration of antidiuretic effect may outlast plasma levels due to receptor binding.
Not extensively metabolized; primarily excreted unchanged in urine. A small fraction may be metabolized by liver or kidney peptidases.
Primarily metabolized in the liver; CYP450 enzymes not significantly involved.
Desmopressin is primarily excreted renally, with approximately 60-70% of the dose recovered unchanged in urine within 24 hours. The remaining fraction is metabolized hepatically and eliminated via feces.
Renal (primarily as unchanged drug via glomerular filtration and tubular secretion; ~65% of an intravenous dose excreted unchanged in urine within 24 hours); fecal (~5–10% of an oral dose); minimal biliary elimination.
Desmopressin exhibits low protein binding, approximately 1-2%, primarily to albumin.
Approximately 1% bound to plasma proteins (negligible binding; primarily to albumin).
Volume of distribution is 0.2-0.4 L/kg, indicating distribution primarily in extracellular fluid.
0.2–0.3 L/kg. Clinical meaning: Low Vd indicates limited extravascular distribution; mostly confined to extracellular fluid.
Intranasal: 10-20%; Oral: 5-10% due to extensive first-pass metabolism.
Oral: 0.1–0.5% (low due to enzymatic degradation in GI tract and extensive first-pass metabolism); Subcutaneous: ~85–90%; Intranasal: ~3–5% (variable due to nasal absorption and metabolism).
No specific adjustment; caution in severe impairment (e GFR <15 m L/min).
GFR >50 m L/min: No adjustment. GFR 10-50 m L/min: Caution, reduce dose by 50% or extend interval. GFR <10 m L/min: Contraindicated or avoid use.
No specific adjustment; limited data in Child-Pugh C; use cautiously.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Children ≥6 years: same as adult; intranasal 1 spray (1.5 mg) 1 hour before bedtime. Do not exceed 2 sprays per day.
Intranasal: Infants and children, 5 mcg (0.5 spray) once daily, titrate to effect. Oral: 0.05-0.1 mg three times daily, weight-based (0.1-1 mcg/kg) but not established.
Use caution due to risk of hyponatremia and hypertension; start at lowest effective dose.
Initiate at lowest effective dose; monitor for hyponatremia and fluid retention; adjust based on renal function.
No FDA black box warning exists for STIMATE.
No FDA black box warning.
Hyponatremia and fluid overload with water intoxication,Seizures due to hyponatremia,Thrombotic events (in patients with predisposing factors),Caution in patients with cystic fibrosis, coronary artery disease, or hypertension,Risk of arterial or venous thrombosis, especially with desmopressin treatment for bleeding disorders,Elderly patients at increased risk of hyponatremia
Fluid restriction required to prevent water intoxication and hyponatremia,Monitor serum sodium in at-risk patients (e.g., elderly, cystic fibrosis),Use with caution in patients with hypertension, coronary artery disease, or renal impairment,Allergic reactions possible
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Known platelet-type von Willebrand disease (pseudo-von Willebrand disease),Unstable angina, decompensated heart failure, or severe coronary artery disease
Hypersensitivity to desmopressin or components,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Primary nocturnal enuresis in patients with polydipsia or fluid imbalance
No specific food interactions. However, avoid excessive fluid intake (more than needed to satisfy thirst) while taking STIMATE to reduce risk of water intoxication and hyponatremia. For patients with nocturnal enuresis, restrict fluids 1 hour before bedtime.
Avoid excessive fluid intake, especially water, within 1 hour before and after dosing. Limit foods with high water content (e.g., soups, melons). No specific food-drug interactions; focus on fluid restriction to prevent hyponatremia.
Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; theoretical risk of teratogenicity. Second trimester: Avoid due to risk of preterm labor. Third trimester: May induce premature labor; use only if clearly needed for diabetes insipidus.
Desmopressin (MINIRIN) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. In humans, limited data show no increased risk of major birth defects. However, due to antidiuretic effects, monitor for hyponatremia and fluid overload during pregnancy, particularly in third trimester when plasma volume increases.
Desmopressin is excreted in breast milk in low amounts; M/P ratio not established. No adverse effects reported in infants. Use with caution, especially in nursing mothers with preeclampsia due to potential for water intoxication.
Desmopressin is excreted into breast milk in very small amounts; M/P ratio is approximately 0.3. It is generally considered compatible with breastfeeding. Because it is a peptide, oral bioavailability in the infant is low. Monitor infant for signs of water retention or electrolyte imbalance, though risk is minimal.
Increased plasma volume and enhanced renal clearance in pregnancy may reduce desmopressin concentrations; dose adjustments may be required. Monitor clinical response and adjust dose based on urine output and plasma sodium. No standard dose adjustment; individualize therapy.
During pregnancy, plasma volume increases and clearance of desmopressin may increase. No standard dose adjustment is required, but patients with diabetes insipidus may need dose titration based on urine output and serum sodium. Avoid overcorrection of hyponatremia. Postpartum, dose should be reduced due to rapid fluid shifts.
STIMATE (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in patients with increased fluid intake, elderly, or those on medications that increase ADH (e.g., SSRIs, NSAIDs). Use with caution in patients with renal impairment, cardiovascular disease, or cystic fibrosis. Avoid use in patients with primary polydipsia or uncontrolled hypertension. For nocturnal enuresis, limit fluid intake 1 hour before dose. Start at lowest effective dose and titrate. Can be administered intranasally, orally, or intravenously. Intranasal route is not recommended for infants due to variable absorption.
Desmopressin (Minirin) is a synthetic analog of vasopressin; avoid use in patients with hyponatremia or impaired renal function. Monitor sodium levels especially in elderly and young children. Intranasal absorption may be variable with nasal congestion; consider using oral or injectable forms in such cases. For nocturnal enuresis, restrict fluids 1 hour before dose to reduce hyponatremia risk.
Take STIMATE exactly as prescribed; do not increase dose or frequency without consulting your doctor.,For nocturnal enuresis: avoid drinking fluids 1 hour before bedtime and use the bathroom before going to sleep.,Report signs of hyponatremia: headache, nausea, vomiting, confusion, muscle cramps, weakness, or seizures.,Do not use STIMATE if you have allergies to desmopressin or any ingredient in the formulation.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease, heart disease, or cystic fibrosis.,Store STIMATE at room temperature away from moisture and heat; do not freeze.,For intranasal spray: prime the pump before first use and when not used for 7 days. Blow nose gently before use and do not sniff deeply after spraying.,Do not share your medication with others.
Do not drink more than 250 m L (8 oz) of fluids within 1 hour before or after taking Minirin to prevent water intoxication.,For intranasal spray, prime pump before first use or if not used for >1 week. Blow nose gently before administration.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Report signs of hyponatremia: headache, nausea, vomiting, confusion, seizures, or unusual fatigue.,If using for bedwetting, take at bedtime and ensure voiding just before sleep.
"Lumacaftor, a component of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector therapy, is a strong inducer of cytochrome P450 (CYP) 3A4 enzymes. Concurrent administration with norgestimate, a progestin component of oral contraceptives that is metabolized primarily by CYP3A4, can significantly reduce norgestimate plasma concentrations. This reduction may diminish the contraceptive efficacy and potentially lead to unintended pregnancy, as well as reduced therapeutic effects for other indications of norgestimate."
"Norgestimate, a progestin component of oral contraceptives, may induce the activity of UDP-glucuronosyltransferases (UGTs), particularly UGT1A1 and UGT2B7, which are involved in the glucuronidation and clearance of miglustat. This enzyme induction can decrease miglustat plasma concentrations, potentially reducing its therapeutic efficacy in treating Gaucher disease or Niemann-Pick type C disease. The clinical outcome could be diminished disease control, requiring dose adjustments or alternative therapy."
"Oxcarbazepine, a potent inducer of cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferases (UGTs), significantly decreases the serum concentration of norgestimate by enhancing its hepatic metabolism. This metabolic induction converts norgestimate to less active metabolites, reducing its contraceptive efficacy. Clinically, this interaction may lead to unintended pregnancy in women using hormonal contraceptives containing norgestimate, as well as potential breakthrough bleeding or irregular menstrual cycles."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE vs MINIRIN, answered by our medical review team.
STIMATE is a Antidiuretic Hormone Analog that works by Desmopressin acetate is a synthetic analog of the natural pituitary hormone 8-arginine vasopressin (ADH). It acts as a V2 receptor agonist in the renal collecting ducts, increasing water permeability and promoting water reabsorption, thereby reducing urine output. It also increases plasma levels of von Willebrand factor and factor VIII via V2 receptor stimulation on endothelial cells.. MINIRIN is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analog of antidiuretic hormone (ADH) that increases water reabsorption in the renal collecting ducts by binding to V2 receptors, leading to increased aquaporin-2 expression and reduced urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE and MINIRIN depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE is: Intranasal: 1 spray (1.5 mg) into one nostril, 1 hour prior to voiding or on awakening for bedwetting; maximum 2 sprays per day.. The standard adult dose of MINIRIN is: Adults: 1-2 sprays intranasally (10 mcg each) once daily; for diabetes insipidus, 1-2 sprays once or twice daily. Oral: 0.1-0.2 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE and MINIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE is classified as Category C. Pregnancy Category X. Desmopressin (STIMATE) is contraindicated in pregnancy due to risk of uterine contractions and potential fetal harm. First trimester: No adequate studies; the. MINIRIN is classified as Category C. Desmopressin (MINIRIN) is classified as FDA Pregnancy Category B. No teratogenic effects have been observed in animal studies. In humans, limited data show no increased risk of maj. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.